In a notable development in the pharmaceutical legal landscape, a New York federal judge has accepted the withdrawal of the entire Kirkland & Ellis LLP team from representing Novartis Pharma. This move comes in the wake of a challenge from Regeneron Pharmaceuticals, which sought disqualification of the legal team due to an “unthinkable” conflict of interest. The conflict arose because the team, while at Kirkland, had previously represented Regeneron.
The withdrawal is part of ongoing antitrust litigation concerning Novartis’ eye medication, Eylea. Regeneron’s petition for disqualification suggested that Kirkland & Ellis’ dual involvement with both companies created an untenable situation. This decision is crucial for antitrust proceedings as it reshapes Novartis’ legal strategy going forward.
For further details, view the original article on Law360.